- Home
- ACRV vs MSD Comparison
ACRV vs MSD Comparison
Compare ACRV & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- MSD
- Stock Information
- Founded
- ACRV 2018
- MSD 1993
- Country
- ACRV United States
- MSD United States
- Employees
- ACRV N/A
- MSD N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- MSD Trusts Except Educational Religious and Charitable
- Sector
- ACRV Health Care
- MSD Finance
- Exchange
- ACRV Nasdaq
- MSD Nasdaq
- Market Cap
- ACRV 170.3M
- MSD 159.9M
- IPO Year
- ACRV 2022
- MSD N/A
- Fundamental
- Price
- ACRV $5.65
- MSD $8.02
- Analyst Decision
- ACRV Strong Buy
- MSD
- Analyst Count
- ACRV 5
- MSD 0
- Target Price
- ACRV $22.40
- MSD N/A
- AVG Volume (30 Days)
- ACRV 50.9K
- MSD 70.2K
- Earning Date
- ACRV 11-13-2024
- MSD 01-01-0001
- Dividend Yield
- ACRV N/A
- MSD 11.26%
- EPS Growth
- ACRV N/A
- MSD N/A
- EPS
- ACRV N/A
- MSD N/A
- Revenue
- ACRV N/A
- MSD N/A
- Revenue This Year
- ACRV N/A
- MSD N/A
- Revenue Next Year
- ACRV N/A
- MSD N/A
- P/E Ratio
- ACRV N/A
- MSD N/A
- Revenue Growth
- ACRV N/A
- MSD N/A
- 52 Week Low
- ACRV $3.19
- MSD $6.11
- 52 Week High
- ACRV $11.90
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- ACRV 41.71
- MSD 64.83
- Support Level
- ACRV $5.36
- MSD $7.56
- Resistance Level
- ACRV $6.00
- MSD $7.97
- Average True Range (ATR)
- ACRV 0.52
- MSD 0.14
- MACD
- ACRV -0.01
- MSD 0.05
- Stochastic Oscillator
- ACRV 17.74
- MSD 98.53
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.